

The ToxCast Chemical Prioritization Program at the US EPA

Keith Houck
National Center for Computational Toxicology
Office of Research and Development
houck.keith@epa.gov



12 November 2015
UCLA


Outline

- **The Problem**
- **Addressing the Problem**
 - Chemicals
 - Hazard Predictions for Prioritization
 - Developing data – high-throughput *in vitro*
 - Selective chemical analysis
 - Nonselective chemical analysis
 - Mechanistic interpretation
 - High-Throughput Toxicokinetics – estimating daily dose
 - High-Throughput Exposure
- **Putting it all together**
 - Cost efficient and rapid prioritization

Problem Statement




Too many chemicals to test with standard animal-based methods

– Cost, time, animal welfare




Need for better mechanistic data

- Determine human relevance
- What is the Mode of Action (MOA) or Adverse Outcome Pathway (AOP)?



In 2007, NRC Transformed Toxicology with a Future View


I envision the future of safety
testing... in vitro assays... human
cells... toxicity pathways...



Tox21 Vision: Transforming Toxicity Testing




**National Center for Advancing
Translational Sciences (NCATS)**
<http://www.ncats.nih.gov/>



ToxCast / Tox21 Overall Strategy


- Identify targets or pathways linked to toxicity (AOP focus)
- Identify/develop high-throughput assays for these targets or pathways
- Develop predictive systems models
 - *in silico/in vitro* → *in vivo*
 - human focus
- Use predictive models (qualitative):
 - Prioritize chemicals for targeted testing
 - Suggest / distinguish possible AOP / MOA for chemicals
- *High-throughput Exposure Predictions*
- *High-throughput Risk Assessments*







Toxicity Testing in the 21st Century


*“The committee envisions a future in which tests based on **human cell systems** can serve as better models of human biologic responses than apical studies in different species.”*

*“The committee therefore believes that, given a sufficient research and development effort, **human cell systems** have the potential to largely supplant testing in animals.”*




ToxCast & Tox21: Chemicals, Data and Release Timelines

Set	Chemicals	Assays	Endpoints	Completion	Available
ToxCast Phase I	 293	~600	~700	2011	Now
ToxCast Phase II	 767	~600	~700	03/2013	Now
ToxCast E1K	 800	~50	~120	03/2013	Now
Tox21	 ~9000	~80	~150	Ongoing	Ongoing




ToxCast PhI & PhII 1060: # Compounds per Inventory




Hazard Predictions for Prioritization: High-Throughput Screening (HTS)



Robots




96-, 384-, 1536 Well Plates




Chemical Exposure




Cell Population



Pathway



Target Biology (e.g.,
Estrogen Receptor)




Assay Selection Strategy

- Several rounds of solicitations for broad ranges of assays covering target gene families, critical pathways, toxicity phenotypes, complex cell culture systems, gene expression, developmental pathways
- Required:
 - Ability to efficiently screen thousands of chemicals
 - Existing, *validated* assays
 - Quality Assurance/Quality Control program
- Lack of extensive list of defined toxicity pathways/targets required broad approach
- Currently refining assay used based on quality and utility of data generated



ToxCast Assays (>700 endpoints)



Assay Provider

ACEA
Apredica
Attagene
BioReliance
BioSeek
CeeTox
CellzDirect
Tox21/NCATS
NHEERL MESC
NHEERL Zebrafish
NovaScreen (Perkin Elmer)
Odyssey Thera
Vala Sciences

Biological Response

cell proliferation and death
cell differentiation
Enzymatic activity
mitochondrial depolarization
protein stabilization
oxidative phosphorylation
reporter gene activation
gene expression (qNPA)
receptor binding
receptor activity
steroidogenesis

Target Family

response Element
transporter
cytokines
kinases
nuclear receptor
CYP450 / ADME
cholinesterase
phosphatases
proteases
XME metabolism
GPCRs
ion channels

Assay Design

viability reporter
morphology reporter
conformation reporter
enzyme reporter
membrane potential reporter
binding reporter
inducible reporter

Readout Type

single
multiplexed
multiparametric

Cell Format

cell free
cell lines
primary cells
complex cultures
free embryos

Species

human
rat
mouse
zebrafish
sheep
boar
rabbit
cattle
guinea pig

Tissue Source

Lung	Breast
Liver	Vascular
Skin	Kidney
Cervix	Testis
Uterus	Brain
Intestinal	Spleen
Bladder	Ovary
Pancreas	Prostate
Inflammatory	Bone

Detection Technology

qNPA and ELISA
Fluorescence & Luminescence
Alamar Blue Reduction
Arrayscan / Microscopy
Reporter gene activation
Spectrophotometry
Radioactivity
HPLC and HPEC
TR-FRET

List of assays and related information at: <http://www.epa.gov/ncct/>

ToxCast Results: 1051 Chemicals x 791 Assay Readouts

ACEA: red

Attagene: orange


Apredica: black

BioSeek: green

Novascreen: gray

Tox21: violet

OT: blue



Assays

Chemicals

Table 2 Top 20 most promiscuous chemicals ^a			
Chemical Name	AC50s		
	Total	<=10µM	<=1µM
Phenylmercuric acetate	90	47	20
Mancozeb	88	41	13
Gentian violet	86	51	5
Sodium dodecylbenzenesulfonate	82	19	0
Tributyltin methacrylate	79	48	12
Tributyltin chloride	77	45	9
Mercuric chloride	73	45	14
Perfluorooctane sulfonic acid	72	13	2
{4-[3-(aminomethyl)phenyl]piperidin-1-yl}{5-[(2-fluorophenyl)ethynyl]furan-2-yl}methanone (pharma)	71	25	4
Dodecylbenzene sulfonate triethanolamine (1:1)	66	7	1
SSR241586 (pharma)	66	30	8
Emamectin benzoate	65	14	2
{4-[5-(aminomethyl)-2-fluorophenyl]piperidin-1-yl}{4-bromo-3-methyl-5-propoxythiophen-2-yl}methanone hydrochloride (pharma)	64	19	2
(1R)-1-[(ethoxycarbonyl)oxy]ethyl 1-[[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]methyl]-2-[[1-(propan-2-yl)piperidin-4-yl]carbonyl]-1H-indole-5-carboxylate hydrochloride(pharma)	63	29	2
Maneb	62	31	16
SSR150106 (pharma)	62	41	13
Didecyl dimethyl ammonium chloride	62	30	2
Zamifenacin (pharma)	60	27	11
SSR125047 (pharma)	59	16	3
Metiram	56	16	4

Sipes *et al.*, Chem Res Toxicol. 26:878-95, 2013

ToxCast Results: 1051 Chemicals x 791 Assay Readouts

ACEA: red

Attagene: orange

Apredica: black

BioSeek: green

Novascreen: gray

Tox21: violet

OT: blue






Table 3 Top 20 most promiscuous assays^a


Assay target	Assay category	AC50s		
		Total	<=10μM	<=1μM
hCYP2C19	CYP	264	144	53
hCYP2C9	CYP	152	81	19
rPBR	Transporter	147	62	18
hPXR	Nuclear receptor (subfamily 1)	140	73	35
hNET	Transporter	136	48	13
hPBR	Transporter	117	36	5
hDAT	Transporter	117	45	7
hCYP1A2	CYP	108	60	16
gDAT	Transporter	98	26	4
h5HT7	GPCR (aminergic)	96	35	13
hGR	Nuclear receptor (subfamily 3)	96	35	6
hOpiate_mu	GPCR (other)	92	27	5
hDRD1	GPCR (aminergic)	89	36	9
rNaCh_site2	Ion channel	87	37	13
hCYP2B6	CYP	81	43	16
gSIGMA_NonSelective	Other	80	31	13
gOpiateK	GPCR (other)	75	18	4
rMAOAC	Other enzyme	73	15	6
hAR	Nuclear receptor (subfamily 3)	73	33	8
hBACE	Protease	73	28	3

Sipes *et al.*, Chem Res Toxicol. 26:878-95, 2013

What Did High-Throughput Screening Tell Us?




In Vitro Assay Selectivity as a Starting Point for Chemical Mechanisms Of Action/Adverse Outcome Pathways





Major theme – all assays have false positives and negative

Assays cluster by technology, suggesting technology-specific non-ER activity




Much of this “noise” is reproducible, i.e. it is “assay interference”







Result of interaction of chemical with complex biology in the assay

Our chemical library is only partially “drug-like”

- Solvents
- Surfactants
- Intentionally cytotoxic compounds
- Metals
- Inorganics



Example Agonist, Antagonist, Interference Chemicals




Assay Legend

- A1: bovine ER cell-free radioligand binding (NVS)
- A2: human ER cell-free radioligand binding (NVS)
- A3: mouse ERa cell-free radioligand binding (NVS)
- A4: ERa-ERa protein complementation/FRET 8 hr (OT)
- A5: ERa-ERa protein complementation/FRET 24 hr (OT)
- A6: ERa-ERb protein complementation/FRET 8 hr (OT)
- A7: ERa-ERb protein complementation/FRET 24 hr (OT)
- A8: ERb-ERb protein complementation/FRET 8 hr (OT)
- A9: ERb-ERb protein complementation/FRET 24 hr (OT)
- A10: ERE chromatin binding (PCA/FRET) 8 hr (OT)
- A11: ERE chromatin binding (PCA/FRET) 24 hr (OT)
- A12: ERa-TRANS reporter gene (ATG)
- A13: ERE-CIS reporter gene (ATG)
- A14: ERa beta-lactamase agonist reporter gene (Tox21)
- A15: ERa luciferase-BG1 agonist reporter gene (Tox21)
- A16: T47D real-time cell proliferation (ACEA)
- A17: ERa beta-lactamase antagonist reporter gene (Tox21)
- A18: ERa luciferase-BG1 antagonist reporter gene (Tox21)

Receptor Legend

- R1: Agonist Model
- R2: Antagonist Model
- R3: Interference: cell-free radioligand binding (NVS)
- R4: Interference: protein complementation (PCA)/FRET (OT)
- R5: Interference: chromatin binding PCA/FRET (OT)
- R6: Interference: RNA reporter gene agonist (ATG)
- R7: Interference: protein reporter gene agonist (Tox21)
- R8: Interference: cell proliferation (ACEA)
- R9: Interference: protein reporter antagonist (Tox21)

Reference Chemical Classification





Notice

Use of High Throughput Assays and Computational Tools; Endocrine Disruptor Screening Program; Notice of Availability and Opportunity for Comment

A Notice by the Environmental Protection Agency on 06/19/2015

This document has a comment period that ends in 53 days (08/18/2015)

SUBMIT A FORMAL COMMENT

ACTION Notice.

SUMMARY

This document describes how EPA is planning to incorporate an alternative scientific approach to screen chemicals for their ability to interact with the endocrine system. This will improve the Agency's ability to fulfill its statutory mandate to screen pesticide chemicals and other substances for their ability to cause adverse effects by their interaction with the endocrine system. The approach incorporates validated high throughput assays and a computational model and, based on current research, can serve as an alternative for some of the current assays in the Endocrine Disruptor Screening Program (EDSP) Tier 1 battery. EPA has partial screening results for over 1800 chemicals that have been evaluated using high throughput assays and a computational model for the estrogen receptor pathway. In the future, EPA anticipates that additional alternative methods will be available for EDSP chemical screening based on further advancements of high throughput assays and computational models for other endocrine pathways. Use of these alternative methods will accelerate the pace of screening, decrease costs, and reduce animal testing. In addition, this approach advances the goal of providing sensitive, specific, quantitative, and efficient screening using alternative test methods to some assays in the Tier 1 battery to protect human health and the environment.

Back to Top Previous Document Next Document

LEGAL DISCLAIMER

Font Controls

PDF DEV
PRINT
PUBLIC INSPECTION

Publication Date:
Friday, June 19, 2015

Agency:
Environmental Protection
Agency

Dates:
Comments must be received on
or before August 18, 2015.

Comments Close:
08/18/2015

Entry Type:
Notice

Action:
Notice.

Document Citation:
80 FR 35350

Page:
35350 -35355 (6 pages)

Agency/Docket Numbers:
EPA-HQ-OPPT-2015-0305
FRL-9928-69


Document Number:
2015-15182

“The approach incorporates validated high-throughput assays and a computational model and, based on current research, can serve as an alternative for some of the current assays in the Endocrine Disruptor Screening Program (EDSP) Tier 1 battery.”

TABLE OF CONTENTS

Back to Top

- DATES:
- ADDRESSES:
- FOR FURTHER INFORMATION CONTACT:




Office of Research and Development
National Center for Computational Toxicology

And No Effect Levels



Animated Spider Plot
CAFFEINE




Non-Selectivity Closely Aligned with Cytotoxicity

± 3 SD for burst

Cytotox assays


80-05-7 : Bisphenol A



AC50s for ER
assays


Histogram
counting hits

1034-01-1 : Octyl gallate




Relatively narrow concentration range
going from no biological
perturbation and use that to define a
point of departure?
activity/cytotoxicity

Understanding Mechanisms: BioMAP Profiling Assays



Inferred Mechanism of Toxicity: nano Silver



- **Ciclopirox – inhibitor of Na⁺K⁺ATPase**
- **Toxicity of silver is associated with inhibition of Na⁺K⁺ATPase (PMID: 6240533)**



Unsupervised Clustering using Self Organizing Maps Yields Mechanistic Classes


- Chemicals analyzed at single conc level to minimize polypharmacology effect
- Self Organizing Maps (SOM): 10X10 Array/100 Clusters

Examples of clusters that emerged from the SOM analysis

Norm. method cluster(s)]	Cluster count	Common activity	Example compounds: known associations	Example compounds: novel associations
Chemical [1]	78	Analgesics	Aspirin Indomethacin Celecoxib Diclofenec Darbufelone Clove leaf oil Eugenol Isoeugenol	Propyl gallate Fluridone
Chemical [65]	31	Steroid hormone receptor modulators	Cyproterone acetate Norgestrel Progesterone 17-hydroxyprogesterone Mifepristone	Mirex Donated pharma: PPAR pan agonist A3 adenosine receptor antagonist
Chemical [57, 67]	52	AHR ligands	Hydroquinone 4-chloro-1,2-diaminobenzene 1,2-phenylenediamine Fenaminosulf	Color Index. C.I. Solvent yellow 14
Chemical [48]	27	Estrogen receptor pathway modulators	Clomiphene citrate Tamoxifen citrate Fulvestrant Raloxifene hydrochloride Tamoxifen 4-hydroxytamoxifen	Cyclopamine Amiodarone hydrochloride Haloperidol Reserpine Donated pharma: NK1 receptor antagonist Bradykinin B1 receptor antagonist Lipid-lowering agent
Assay [46]	29	TNF α inhibition	All-trans retinoic acid Donated pharma: PDE inhibitors (8 compounds)	Terbutylazine Donated pharma: GABA $_A$ 1 receptor antagonist
Assay [39]	31	SAA upregulation	Prednisone Dexamethasone Corticosterone Triamcinolone	Coumarin 4-octylphenol Cyclohexanol Pentaerythritol
Assay [90,100]	58	Potent cytotoxicants	Tributyltin methacrylate Tributyltin chloride Gentian violet Didecyldimethylammonium chloride Triclosan Phenylmercuric acetate	Octyl gallate 4-Nonylphenol 9-Phenanthrol Donated pharma: Factor Xa inhibitor CCK1R agonist Mast cell tryptase inhibitor

Hypothesis Generation Example

Blood coagulation *in vivo*






Unsupervised Clustering using Self Organizing Maps Yields Mechanistic Classes

- Chemicals analyzed at single conc level to minimize polypharmacology effect
- Self Organizing Maps (SOM): 10X10 Array/100 Clusters


Examples of clusters that emerged from the SOM analysis


Norm. method cluster(s)]	Cluster count	Common activity	Example compounds: known associations	Example compounds: novel associations
Chemical [1]	78	Analgesics	Aspirin Indomethacin Celecoxib Diclofenec Darbufelone Clove leaf oil Eugenol Isoeugenol	Propyl gallate Fluridone
Chemical [65]	31	Steroid hormone receptor modulators	Cyproterone acetate Norgestrel Progesterone 17-hydroxyprogesterone Mifepristone	Mirex Donated pharma: PPAR pan agonist A3 adenosine receptor antagonist
Chemical [57, 67]	52	AHR ligands	Hydroquinone 4-chloro-1,2-diaminobenzene 1,2-phenylenediamine Fenaminosulf	Color Index. C.I. Solvent yellow 14
Chemical [48]	27	Estrogen receptor pathway modulators	Clomiphene citrate Tamoxifen citrate Fulvestrant Raloxifene hydrochloride Tamoxifen 4-hydroxytamoxifen	Cyclopamine Amiodarone hydrochloride Haloperidol Reserpine Donated pharma: NK1 receptor antagonist Bradykinin B1 receptor antagonist Lipid-lowering agent
Assay [46]	29	TNF α inhibition	All-trans retinoic acid Donated pharma: PDE inhibitors (8 compounds)	Terbutylazine Donated pharma: GABA $_A$ 1 receptor antagonist
Assay [39]	31	SAA upregulation	Prednisone Dexamethasone Corticosterone Triamcinolone	Coumarin 4-octylphenol Cyclohexanol Pentaerythritol
Assay [90,100]	58	Potent cytotoxicants	Tributyltin methacrylate Tributyltin chloride Gentian violet Didecylidimethylammonium chloride Triclosan Phenylmercuric acetate	Octyl gallate 4-Nonylphenol 9-Phenanthrol Donated pharma: Factor Xa inhibitor CCK1R agonist Mast cell tryptase inhibitor

Clusters 57/67 and Relationship to ATG Reporter Gene AHR Activity (85% positive)



Insights in to Mechanisms: BioMap Profiling Assays






31
Kleinstreuer et al. *Nature Biotech.* 2014

Tox21 qHTS Assay: AhR Screening

- Ligand-dependent transcription factor activated by structurally diverse natural and synthetic ligands
- Critical roles in biological processes (development, inflammation)
- Mediates adaptive and toxic response to chemicals
 - HAHs - halogenated aromatic hydrocarbons
 - PAHs – polycyclic aromatic hydrocarbons
- Third-generation CALUX AhR-responsive reporter gene bioassay
 - Human HepG2 cells (HG2L7.5c1)
- Tox21 8.5K Chemical library
 - Environmental, pesticide, industrial, food use, drugs
 - 1536 well-plate format with Tox21 robot
 - 15 concentrations screened in triplicate




Tox21 AhR Assay Results


(A)

qHTS Results Summary	
Number of HITS	768
Percentage of HITS	9.2
Concordance (Percentage)	94.3


(B)



(C)



Determining Toxicity (dioxin-like effects): Follow-up Assay Strategy



Dioxin-like vs Non-dioxin-like Effects

HepaRG gene
expression assay

Chemical ID	CYP1A1	CYP1A2	UGT1A1	IGFBP-1
DMSO	-	-	-	-
20069	+	+	+	+
21135	+	+	+	+
20529	+	+	+	-

Zebrafish larvae
development assay



Advantages of Tiered Screening Approach

C.I. Solvent Yellow

IARC Category 3 carcinogen

Trace levels found in food products


Tumeric, curry, chili powders

- 4.8 to 12.1 mg/g

Impurities in color additives

- 0.008 µg/mL - FD&C Yellow no. 6
- 0.011 µg/mL - D&C Orange no. 4

(Fonovich 2013)



Toxic





Non-toxic

1,4-Dihydroxy-2-naphthoic acid

Probiotic bacterial metabolite
isolated from swiss cheese

Inhibits colitis (Fukumoto et al. 2014)




High-Throughput Toxicokinetics (HTTK)

Reverse Toxicokinetics

High-Throughput Toxicokinetics (*In Vitro* Dosimetry)

- **Problem:** How to estimate daily exposure dose from *in vitro* media concentration
- Use Reverse Toxicokinetics (RTK)
 - very simple 2-parameter PK models
 - *in vitro* measurements of disappearance of parent compound and serum binding values
- Provides scaling from concentration in which there is *in vitro* biological activity to *in vivo* activity dose (mg/kg/day)


High-Throughput Toxicokinetics



- Combine experimental data w/ PK Model to estimate dose / concentration scaling
- RatCast: Same experiment, but with rat hepatocytes and plasma

(Rotroff *et al*, ToxSci 2010, Wetmore *et al*, ToxSci 2012)

Combining *in vitro* activity and dosimetry



Exposure

ExpoCast: High-throughput exposure predictions




Exposure

ExpoCast: High-Throughput Exposure Predictions

- **Exposure science lags behind**
 - Most models require extensive information on production, use, fate and transport and rely on empirical data (*no measurement = no exposure?*)
- **ExpoCast**
 - Exposure predictions based on pChem, production values, fate and transport, and product use categories (e.g., industrial, pesticide use, consumer personal care)
 - Industrial vs consumer use
 - Yields exposure estimates and Bayesian confidence

Exposure Predictions for 7968 Chemicals & Comparison to NHANES



- NHANES – US National Study – measures exposures in human serum and urine
- Chemicals currently monitored by NHANES are distributed throughout the predictions

Putting it All Together

HT Prioritization


Risk is the product of hazard and exposure

There are thousands of chemicals in commerce, most without enough data for risk evaluation

High-throughput *in vitro* methods beginning to bear fruit on potential hazard for many of these chemicals


Methods exist for approximately converting these *in vitro* results to daily doses needed to produce similar levels in a human (IVIVE)

What can we say about exposure with the limited data we have?




Judson *et al.*, (2011)
Chemical Research in Toxicology

Combining 2nd Generation ExpoCast Exposure Predictions with Predicted Hazard



Public Data Access using iCSS Dashboard





NCCT/ORD/USEPA

NCATS/NIH

- Menghang Xia
- Ruili Huang

North Carolina State University

- Seth Kullman
- Anthony Planchart

University of California at Davis

- Mike Dennison
- Anatoly Soshilov

The Hamner Institute

- Barbara Wetmore

BioSeek, a division of DiscoverRx

- Ellen Berg
- Mark Polokoff
- Jian Yang

NCCT 2014